The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features James Sapirstein, President & CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX).
AzurRx currently has two ongoing clinical trials for MS1819. The first is a Phase 2 Cystic Fibrosis Combination Trial examining MS1819 in combination with PERT, which is expected to produce topline data in Q2 2021.
Up next in 5
Commenting is only available to members with access. Sign In